These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3534757)

  • 21. Evaluation of pefloxacin activity against recent clinical isolates.
    Lembo M; Covelli B; Nani E; Lavitola A
    J Chemother; 1991 Jan; 3 Suppl 1():51-3. PubMed ID: 12041785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activities of newer quinolones against Legionella group organisms.
    Greenwood D; Laverick A
    Lancet; 1983 Jul; 2(8344):279-80. PubMed ID: 6135099
    [No Abstract]   [Full Text] [Related]  

  • 23. WIN 57273 is bactericidal for Legionella pneumophila grown in alveolar macrophages.
    Edelstein PH; Edelstein MA
    Antimicrob Agents Chemother; 1989 Dec; 33(12):2132-6. PubMed ID: 2619277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of lomefloxacin (NY-198 or SC 47111), ciprofloxacin, and erythromycin against 100 clinical Legionella strains.
    Edelstein PH; Gaudet EA; Edelstein MA
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):93S-95S. PubMed ID: 2791505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Susceptibility of Legionella pneumophila to eight antimicrobial agents including four macrolides under different assay conditions.
    Liebers DM; Baltch AL; Smith RP; Hammer MC; Conroy JV
    J Antimicrob Chemother; 1989 Jan; 23(1):37-41. PubMed ID: 2526110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing.
    Stout JE; Sens K; Mietzner S; Obman A; Yu VL
    Int J Antimicrob Agents; 2005 Apr; 25(4):302-7. PubMed ID: 15784309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro antibacterial activity of irloxacin (E-3432) on clinical isolates.
    Coll R; Esteve M; Moros M; Xicota MA; Parés J
    Drugs Exp Clin Res; 1987; 13(2):75-7. PubMed ID: 3582134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections.
    Naber KG; Sörgel F; Gutzler F; Bartosik-Wich B
    Infection; 1985; 13(5):219-24. PubMed ID: 2933340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative antibacterial activity of new quinolone-carboxylic acid derivatives.
    Mitsuhashi S
    Rev Infect Dis; 1988; 10 Suppl 1():S27-31. PubMed ID: 3347811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [In vitro activity of 5 new quinolones against Gardnerella vaginalis].
    Lefevre JC; Gaubert E; Lareng MB
    Pathol Biol (Paris); 1989 May; 37(5):394-6. PubMed ID: 2550875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sensitivity and resistance of Legionella pneumophila to some antibiotics and combinations of antibiotics.
    Moffie BG; Mouton RP
    J Antimicrob Chemother; 1988 Oct; 22(4):457-62. PubMed ID: 3204075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Modulation by quinolones of the in vitro proliferative response of splenic cells of the mouse and IL 1 production].
    Guenounou M; Ronco E; Kodari E; Vacheron F; Momrikof V
    Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):785-9. PubMed ID: 3309816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative postantibacterial activities of pefloxacin, ciprofloxacin, and ofloxacin against intracellular multiplication of Legionella pneumophila serogroup 1.
    Rajagopalan-Levasseur P; Dournon E; Dameron G; Vilde JL; Pocidalo JJ
    Antimicrob Agents Chemother; 1990 Sep; 34(9):1733-8. PubMed ID: 2285286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of Legionella pneumophila multiplication within human macrophages by antimicrobial agents.
    Vildé JL; Dournon E; Rajagopalan P
    Antimicrob Agents Chemother; 1986 Nov; 30(5):743-8. PubMed ID: 3492176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro antibiotic susceptibility of Legionellaceae: search for alternative antimicrobial drugs.
    Traub WH; Spohr M
    Chemotherapy; 1984; 30(3):182-7. PubMed ID: 6734305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quinolones in vitro.
    Willems FT
    Pharm Weekbl Sci; 1986 Feb; 8(1):26-8. PubMed ID: 3960690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of SCH 27899 (Ziracin) against Legionella species.
    Edelstein PH; Edelstein MA
    Diagn Microbiol Infect Dis; 1999 Jan; 33(1):59-62. PubMed ID: 9990477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of the Etest to antimicrobial susceptibility testing of Legionella spp.
    Rhomberg PR; Bale MJ; Jones RN
    Diagn Microbiol Infect Dis; 1994 Jul; 19(3):175-8. PubMed ID: 7820999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activities of ciprofloxacin, norfloxacin, pipemidic acid, cinoxacin, and nalidixic acid against Chlamydia trachomatis.
    Heessen FW; Muytjens HL
    Antimicrob Agents Chemother; 1984 Jan; 25(1):123-4. PubMed ID: 6230988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare.
    Fenlon CH; Cynamon MH
    Antimicrob Agents Chemother; 1986 Mar; 29(3):386-8. PubMed ID: 2940969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.